Note 3: Revenue and Expenses continued The table below shows a summary of the Group’s operating revenue by product or service category for the years 30 June 2023 and 30 June 2022: Revenue 2023 US$m 2022 US$m CSL Behring Immunoglobulins 4,675 4,024 Albumin 1,109 1,072 Haemophilia 1,193 1,166 Specialty 1,831 1,792 Other 375 500 CSL Seqirus Egg based vaccines 148 228 Cell culture vaccines 599 486 Adjuvanted egg based vaccines 893 885 Pandemic 156 162 Other (including in-license) 211 178 CSL Vifor Iron 1,009 – Nephrology – Dialysis 771 – Nephrology – Non Dialysis 136 – Other 68 – Total revenue from contracts with customers 13,174 10,493 Other income 136 69 Total operating revenue 13,310 10,562 Expenses 2023 US$m 2022 US$m Borrowing costs 374 143 Lease related interest expense 36 35 Unrealised foreign currency losses/(gains) on debt 22 (13) Fair value losses on financial assets 12 – Total finance costs 444 165 Depreciation of property, plant and equipment (PPE) and right-of-use assets 490 445 Amortisation of intangibles 341 97 Impairment expense – 126 Total depreciation, amortisation and impairment expense 831 668 Write-down of inventory 182 224 Employee benefits expense 3,513 2,804 Foreign exchange currency losses/(gains)10 127 (58) 10 Foreign exchange currency losses/(gains) are recorded net within administration expenses in the statement of comprehensive income. CSL Limited Annual Report 2022/23 125
RkJQdWJsaXNoZXIy MjE2NDg3